Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 15/20 | 1.00 |
| ▸ | PIM1 | P11309 | 2/20 | 0.64 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.64 |
| ▸ | AURKA | O14965 | 1/20 | 0.64 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.64 |
| ▸ | JAK2 | O60674 | 1/20 | 0.64 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.64 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.64 |
| ▸ | PAK4 | O96013 | 1/20 | 0.64 |
| ▸ | ABL1 | P00519 | 1/20 | 0.64 |
| ▸ | CSF1R | P07333 | 1/20 | 0.64 |
| ▸ | RET | P07949 | 1/20 | 0.64 |
| ▸ | IGF1R | P08069 | 1/20 | 0.64 |
| ▸ | MET | P08581 | 1/20 | 0.64 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.64 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.64 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.64 |
| ▸ | PRKACA | P17612 | 1/20 | 0.64 |
| ▸ | FLT1 | P17948 | 1/20 | 0.64 |
| ▸ | LTK | P29376 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29443212 | 1.00 | PARP1 (1.00) | PARP1PIM1RPS6KA3AURKADAPK3 | |
| Trifluoroacetic Acid SCHEMBL31483798 | 0.87 | PARP1 (0.75) | PARP1PIM1RPS6KA3AURKADAPK3 | |
| SCHEMBL12068009 | 0.79 | PARP1 (0.66) | PARP1PIM1RPS6KA3AURKADAPK3 | |
| SCHEMBL16006387 | 0.79 | PARP1 (0.65) | PARP1PIM1RPS6KA3AURKADAPK3 | |
| SCHEMBL1387233 | 0.78 | PARP1 (0.64) | PARP1PIM1RPS6KA3AURKADAPK3 | |
| SCHEMBL2447579 | 0.78 | PARP1 (1.00) | PARP1PIM1RPS6KA3AURKADAPK3 | |
| SCHEMBL526730 | 0.78 | PARP1 (1.00) | PARP1PIM1RPS6KA3AURKADAPK3 | |
| SCHEMBL21895445 | 0.78 | PARP1 (1.00) | PARP1PIM1RPS6KA3AURKADAPK3 | |
| SCHEMBL20435416 | 0.78 | PARP1 (0.64) | PARP1PIM1RPS6KA3AURKADAPK3 | |
| SCHEMBL16097896 | 0.78 | PARP1 (0.64) | PARP1PIM1RPS6KA3AURKADAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106086956-B | Alkaline non-cyanide electrodepositing zinc-nickel alloy additive and its application | 哈尔滨工业大学 | 2019-03-01 | — | — | CN | claimed |
| CN-106086956-A | Alkaline non-cyanide electrodepositing zinc-nickel alloy additive and application thereof | 哈尔滨工业大学 | 2016-11-09 | — | — | CN | claimed |
| US-20250059157-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2025-02-20 | — | — | US | disclosed |
| US-12030858-B2 | PARP inhibitors for treating cancer and asthma | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2024-07-09 | — | — | US | disclosed |
| EP-3889145-B1 | 8-CYANO-5-PIPERIDINO-QUINOLINES AS TLR7/8 ANTAGONISTS AND THEIR USES FOR TREATING IMMUNE DISORDERS | MERCK PATENT GMBH (DE) | 2024-02-21 | — | — | EP | disclosed |
| WO-2023217906-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-16 | — | — | WO | disclosed |
| US-20230303514-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2023-09-28 | — | — | US | disclosed |
| CN-116804001-A | Quinazolinone derivative containing pyridinium and preparation method and application thereof | 江苏海洋大学 | 2023-09-26 | — | — | CN | disclosed |
| US-11739071-B2 | Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors | VALO HEALTH, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11739071-B2 | Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors | VALO HEALTH, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11739071-B2 | Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors | VALO HEALTH, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-7217737-B2 | Method and compositions for inhibiting cell proliferative disorders | YISSUM RESEARCH AND DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2007-05-15 | — | — | US | disclosed |
| US-20040242684-A1 | Method and compositions for inhibiting cell proliferative disorders | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM | 2004-12-02 | — | — | US | disclosed |
| US-6596878-B2 | Protein kinase inhibitor compositio; used to treat cell proliferative disorders such as cancers charcterized by over-activity or inappropriate activity HER2 or EGFR. | YISSUM RESEARCH & DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY (IL) | 2003-07-22 | — | — | US | disclosed |
| US-20020068687-A1 | Methods and compositions for inhibiting cell proliferative disorders | CHEN HUI (US) | 2002-06-06 | — | — | US | disclosed |
| US-5789427-A | ANTITUMOR, ANTICANCER AGENTS | SUGEN, INC. (US) | 1998-08-04 | — | — | US | disclosed |
| US-5773476-A | KINASE INHIBITORS | SUGEN, INC. (IL) | 1998-06-30 | — | — | US | disclosed |
| WO-1995024190-A2 | RECEPTOR TYROSINE KINASE INHIBITORS FOR INHIBITING CELL PROLIFERATIVE DISORDERS AND COMPOSITIONS THEREOF | SUGEN, INC. (US) | 1995-09-14 | — | — | WO | disclosed |
| US-5401745-A | Cardiovascular disorders or hypotensive agents | MERCK & CO., INC. (US) | 1995-03-28 | — | — | US | disclosed |
| WO-1994021259-A1 | QUINAZOLINONES SUBSTITUTED WITH PHENOXYPHENYLACETIC ACID DERIVATIVES | MERCK & CO., INC. (US) | 1994-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303514-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | PARP1 866/4885PIM1 3665/4885RPS6KA3 1953/4885 |
| US-11739071-B2 | Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors | USP7, UBQLN1, UBA7 | PARP1 997/4885PIM1 3951/4885RPS6KA3 856/4885 |
| US-20040242684-A1 | Method and compositions for inhibiting cell proliferative disorders | ERBB2, EGFR, MKI67 | PARP1 856/4885PIM1 583/4885RPS6KA3 400/4885 |
| US-12030858-B2 | PARP inhibitors for treating cancer and asthma | PARP1, PARP2, PARP11 | PARP1 1/4885PIM1 652/4885RPS6KA3 943/4885 |
| US-20250059157-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | PARP1 866/4885PIM1 3665/4885RPS6KA3 1953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.